GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (SHSE:688331) » Definitions » Short-Term Capital Lease Obligation

RemeGen Co (SHSE:688331) Short-Term Capital Lease Obligation : ¥62 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is RemeGen Co Short-Term Capital Lease Obligation?

RemeGen Co's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was ¥62 Mil.

RemeGen Co's quarterly Short-Term Capital Lease Obligation increased from Dec. 2023 (¥58 Mil) to Jun. 2024 (¥63 Mil) but then declined from Jun. 2024 (¥63 Mil) to Dec. 2024 (¥62 Mil).

RemeGen Co's annual Short-Term Capital Lease Obligation declined from Dec. 2022 (¥60 Mil) to Dec. 2023 (¥58 Mil) but then increased from Dec. 2023 (¥58 Mil) to Dec. 2024 (¥62 Mil).


RemeGen Co Short-Term Capital Lease Obligation Historical Data

The historical data trend for RemeGen Co's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Short-Term Capital Lease Obligation Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Capital Lease Obligation
Get a 7-Day Free Trial 42.99 52.45 60.15 58.37 62.30

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.15 61.87 58.37 62.99 62.30

RemeGen Co Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


RemeGen Co Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Industry
Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

No Headlines